Video

Davos 2019 - The Future of Healthcare w/ Ken Mulvany

Feb 4, 2019
HomeNEWSVideo
Davos 2019 - The Future of Healthcare w/ Ken Mulvany
Tagged:
Opinion

Live from Davos at the World Economic Forum, CNBC’s Elizabeth Schulze hosts a fireside chat with our Founder, Ken Mulvany, discussing how BenevolentAI is disrupting the pharma industry and exploring what the future of healthcare could look like.

In 2018 BenevolentAI was named a Technology Pioneer by the World Economic Forum and participated to the World Economic Forum Annual Meeting of the New Champions, held in Tianjin, China where we discussed how using AI can help unlock the world’s most complex operating system - the human body.

Receive our latest news
Featured Posts
News
RECOVERY trial results demonstrate baricitinib reduces deaths in hospitalised COVID-19 patients
Blog
World Health Organization panel strongly recommends the use of baricitinib to treat hospitalised patients with COVID-19
News
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure
Follow us
More Posts

You Might Also Like

News
BenevolentAI Announces Board Changes
BenevolentAI today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company.
May 25, 2022
News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
BenevolentAI Begins Trading On Euronext Amsterdam
BenevolentAI, a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of its business combination with Odyssey Acquisition S.A. on 22 April 2022.
Apr 25, 2022
Video
BenevolentAI · AI-Enabled Drug Discovery
Advanced technologies, combined with an exponential increase in biomedical data and research, provide an unparalleled opportunity to unravel the mysteries of diseases that have gone untreated for too long.
Apr 25, 2022
News
BenevolentAI joins the World Economic Forum’s Global Innovators Community
BenevolentAI joins the World Economic Forum’s Global Innovators Community to help ethically deploy AI to create a more sustainable, inclusive and resilient world.
Apr 21, 2022
Drug programmesINVESTORSPARTNERINGcareers
Contact us →
Company Registration: 09781806
Terms & Conditions
Privacy & Cookies Policy